

1 **Supplementary Table**

2 Table S1. Baseline characteristics of the 243 patients without cirrhosis at enrollment

	Patients with anti-HCV therapy (<i>n</i> =202)	Patients without anti-HCV therapy (<i>n</i> =41)	<i>P</i> value
Age (years)	56 (47–64)	65 (53–70)	0.006
Male (<i>n</i> , %)	92 (45.5%)	23 (56.1%)	0.214
BMI (kg/m ²)	23.8 (22–25.5)	23.8 (21.9–25.6)	0.612
Alcohol use (<i>n</i> , %)	19 (9.9%)	5 (22.7%)	0.082
Diabetes, (<i>n</i> , %)	17 (8.8%)	4 (17.4%)	0.252
AST (IU/L)	52 (32–98)	62 (44–142)	0.810
ALT (IU/L)	47 (28–106)	85 (46–129)	0.989
Albumin (g/dL)	4.2 (4.1–4.4)	4.1 (3.8–4.3)	0.056
INR	1.04 (0.99–1.10)	1.04 (0.97–1.08)	0.779
Platelet ($\times 10^3/\mu\text{L}$)	178 (149–231)	180 (136–208)	0.576
HCV RNA >600,000 IU/mL	113 (57.9%)	20 (64.5%)	0.490
HCV genotype (<i>n</i> , %)			0.894
Type 1	96 (48.7%)	16 (50.0%)	
Other	101 (51.3%)	16 (50.0%)	

3 HCV, hepatitis C virus; BMI, body mass index; AST, aspartate aminotransferase; ALT,

4 alanine aminotransferase; INR, international normalized ratio

Table S2. Cox multivariate regression analysis for the development of HCC in the 243 patients without cirrhosis at enrollment

Variables	Hazard ratio (95% CI)	<i>P</i> value
Platelets ≤ 120 ($\times 10^3/\mu\text{L}$)	2.75 (0.49–15.56)	0.251
Response to anti-HCV therapy		
Untreated control	1	
No SVR	0.25 (0.03–2.26)	0.218
SVR	0.09 (0.01–0.76)	0.028

HCC, hepatocellular carcinoma; HCV, hepatitis C virus; SVR, sustained virologic response